Viking Therapeutics to Report Q2 2025 Financial Results on July 23, 2025

Viking Therapeutics will release Q2 2025 financial results on July 23, 2025. The company is actively advancing clinical programs, including VK2735 and VK2809, and exploring treatments for metabolic disorders like obesity and NASH. However, the company remains in the clinical-stage, and clinical trial uncertainty poses risks. Investors will focus on cash flow, R&D expenditures, and potential revenue streams from partnerships. The success of clinical trials could significantly influence valuation and investor sentiment.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, will release its Q2 2025 financial results on Wednesday, July 23, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results and provide corporate updates [1].

Viking Therapeutics is actively advancing its clinical programs, including VK2735 and VK2809, which have shown promising results in trials. The company is exploring innovative treatments for a range of metabolic disorders, including obesity and non-alcoholic steatohepatitis (NASH). Additionally, Viking is developing therapies for rare diseases such as X-linked adrenoleukodystrophy (X-ALD), demonstrating a broad therapeutic focus [2].

However, Viking Therapeutics remains in the clinical-stage, which means its therapies are not yet commercially available, posing a risk for investors. There is inherent uncertainty in clinical trials, which could impact the timeline and success of product development [2].

From a financial analyst's viewpoint, Viking Therapeutics' upcoming financial results will provide critical insights into the company's fiscal health and operational efficiency. Investors will be keen to assess the company's cash flow, R&D expenditures, and any potential revenue streams from partnerships or collaborations. The progress in clinical trials, particularly for VK2735 and VK2809, could significantly influence the company's valuation and investor sentiment [2].

Viking Therapeutics shares rose to their highest level since February 2025 today, with an intraday gain of 3.40%. Analysts have a consensus rating of Strong Buy and a price target of $97.64, suggesting a substantial upside potential of 218.05% [3]. Recent performance has been robust, with the stock gaining 1.39% on the last trading day, outperforming the broader market.

The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company is predicted to post an EPS of -$0.44, indicating a 120% decline compared to the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of -$1.86 per share and a revenue of $25 million, demonstrating changes of -84.16% and 0%, respectively, from the preceding year [4].

Investors can join the conference call via phone or watch the webcast through Viking's website. A replay will be available until July 30, 2025, and the webcast recording will be accessible for 30 days [1].

References:
[1] https://www.stocktitan.net/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-c8ad2fdkm2u6.html
[2] https://www.gurufocus.com/news/2982741/viking-therapeutics-inc-vktx-to-announce-q2-2025-financial-results-vktx-stock-news
[3] https://www.ainvest.com/news/viking-therapeutics-vktx-soars-3-40-bullish-analyst-sentiment-2507/
[4] https://www.nasdaq.com/articles/viking-therapeutics-inc-vktx-outperforms-broader-market-what-you-need-know